This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
The European Commission has cleared the acquisition of Hospira by Pfizer in phase 1. The clearance is subject to the divestment of some sterile injectable drugs and one biosimilar pipeline.
A CRA team advised and provided economic support to Pfizer during the pre-notification and phase 1 proceedings in front of the European Commission.
For more details, please see the Commission’s press release.
In this episode of The Competitive Edge, Dr. Philip Marsden, co-author of the Furman report into digital competition, talks about specialist tech regulation...
Looking back on the challenges of 2022, we are grateful to our team of talented economists who worked hard to deliver creative and thoughtful analyses...
CRA is a proud sponsor of this event. For more information on this event, click here.
CRA is a proud sponsor of this event. To read more about our nominees, click here. For more information on this event, click here.
